The estimated Net Worth of James E Deerfield Mgmt Hif,... is at least $184 Tisíc dollars as of 28 December 2022. James Hif owns over 336,235 units of Oncorus stock worth over $34,306 and over the last 4 years James sold ONCR stock worth over $149,806.
Sign up
James Hif ONCR stock SEC Form 4 insiders trading
James has made over 5 trades of the Oncorus stock since 2020, according to the Form 4 filled with the SEC. Most recently James sold 336,235 units of ONCR stock worth $87,421 on 28 December 2022.
The largest trade James's ever made was buying 1,562,500 units of Oncorus stock on 29 September 2020 worth over $25,000,000. On average, James trades about 422,833 units every 164 days since 2020. As of 28 December 2022 James still owns at least 284,697 units of Oncorus stock.
You can see the complete history of James Hif stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Oncorus
Over the last 4 years, insiders at Oncorus have traded over $1,276,271 worth of Oncorus stock and bought 2,354,001 units worth $35,555,648 . The most active insiders traders include Ansbert Gadicke, Luke Evnin a James E Deerfield Mgmt Hif,.... On average, Oncorus executives and independent directors trade stock every 34 days with the average trade being worth of $15,538. The most recent stock trade was executed by James E Deerfield Mgmt Hif,... on 28 December 2022, trading 336,235 units of ONCR stock currently worth $87,421.
What does Oncorus do?
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What does Oncorus's logo look like?
Complete history of James Hif stock trades at Graybug Vision a Oncorus
Oncorus executives and stock owners
Oncorus executives and other stock owners filed with the SEC include:
-
Stephen W. Harbin,
COO & Chief of Staff -
Dr. Theodore T. Ashburn M.D., Ph.D.,
Pres, CEO & Director -
Dr. Theodore T. Ashburn,
Pres, CEO & Director -
Dr. Christophe Queva Ph.D.,
Chief Scientific Officer & Sr. VP of Research -
Stephen Harbin,
COO & Chief of Staff -
Dr. Mitchell H. Finer Ph.D.,
Co-Founder & Non-Exec. Chairman -
Dr. Mitchell H. Finer,
Co-Founder & Exec. Chairman -
Chris German,
Controller -
Brian J. Shea,
Director of Legal Counsel & Corp. Sec. -
Richard J. Wanstall M.B.A.,
CFO, Chief Accounting Officer & Treasurer -
Dr. John Mayer Goldberg M.D.,
Sr. VP of Clinical Devel. -
John McCabe M.B.A.,
CFO, Treasurer & Sec. -
Scott A Canute,
Director -
Rick Wanstall,
CFO and Treasurer -
Theodore Ashburn,
President and CEO -
Christophe Queva,
CSO and SVP, Research -
James E Deerfield Mgmt Hif,...,
-
Luke Evnin,
Director -
Oncology Impact Fund L.P.On...,
-
Ansbert Gadicke,
10% owner -
Mitchell H. Finer,
Director -
Bio Ventures 2014, L.P.Fole...,
-
Spencer Nam,
Director -
Sun States Fund, L.P.Mpm As...,
-
Stephen Harbin,
COO and Chief of Staff -
John P. Mc Cabe,
CFO and Treasurer -
Mary Kay Fenton,
Director -
Eric Rubin,
Director -
Barbara Yanni,
Director -
John Mayer Goldberg,
Chief Medical Officer -
James E Deerfield Mgmt Hif,...,
-
Douglas Fambrough,
Director